公开(公告)号：US20200261436A1

公开(公告)日：2020-08-20

申请号：US16061519

申请日：2016-12-13

申请人： MERCK SHARP & DOHME CORP.

发明人： John P. CALDWELL ,  Reynalda DE JESUS ,  Fa-Xiang DING ,  Charles J. GIll ,  Ginny Dai HO ,  Sookhee N. HA ,  Sandra J. KOSEOGLU ,  Marc A. LABROLI ,  Sang Ho LEE ,  Christina MADSEN-DUGGAN ,  Mihir MANDAL ,  Terry ROEMER ,  Jing SU ,  Christopher Michael TAN ,  Zheng TAN ,  Haifeng TANG ,  Hao WANG ,  Christine YANG ,  Shu-Wei YANG

IPC分类号： A61K31/4439 ,  A61K31/407 ,  A61K31/431 ,  C07D413/12 ,  C07D471/04 ,  C07D263/26 ,  C07D495/04 ,  C07D491/048 ,  C07D417/12 ,  C07D413/14 ,  C07D413/06 ,  C07D413/04 ,  C07D498/04 ,  A61K31/4709 ,  A61K31/438 ,  A61K31/421 ,  A61K31/4375 ,  A61K31/422 ,  A61K31/427 ,  A61K31/5377 ,  A61K31/5383 ,  A61P31/04

摘要： Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a β-lactam antibiotic.

公开(公告)号：US20210346364A1

公开(公告)日：2021-11-11

申请号：US17385258

申请日：2021-07-26

申请人： MERCK SHARP & DOHME CORP.

发明人： John P. CALDWELL ,  Reynalda DE JESUS ,  Fa-Xiang DING ,  Charles J. GIll ,  Ginny Dai HO ,  Sookhee N. HA ,  Sandra J. KOSEOGLU ,  Marc A. LABROLI ,  Sang Ho LEE ,  Christina MADSEN-DUGGAN ,  Mihir MANDAL ,  Terry ROEMER ,  Jing SU ,  Christopher Michael TAN ,  Zheng TAN ,  Haifeng TANG ,  Hao WANG ,  Christine YANG ,  Shu-Wei YANG

IPC分类号： A61K31/4439 ,  A61P31/04 ,  A61K31/407 ,  A61K31/421 ,  A61K31/422 ,  A61K31/427 ,  A61K31/431 ,  A61K31/4375 ,  A61K31/438 ,  A61K31/4709 ,  A61K31/5377 ,  A61K31/5383 ,  C07D263/26 ,  C07D413/04 ,  C07D413/06 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D491/048 ,  C07D495/04 ,  C07D498/04

摘要： Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a β-lactam antibiotic.